DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design

• GLE/PIB: 100/40 mg 3 tablets QD
• Patients enrolled in Australia, Canada, Italy, New Zealand, Puerto Rico, Spain, Taiwan, the United Kingdom and the United States

Objective

• Primary endpoint: SVR₁₂ ( HCV < 15 IU/mL)
• Non-inferiority to historical 94% SVR 12 standard-of-care rate, achieved if > 86% (8% margin)

Baseline characteristics

SVR₁₂, %

Adverse events and laboratory abnormalities, N (%)

* 2 related to study drugs : sinusitis (Day 2), abnormal hepatic function (post-treatment week 4)

• One patient experienced mild liver transplant rejection, unrelated to study drugs

Summary

• Glecaprevir/pibrentasvir for 12 weeks achieved a 99% SVR₁₂ rate in patients with liver or kidney transplant and genotype 1-6
• This rate was not inferior to historical standard of care
• Treatment was well-tolerated